DCT and melanoma: A Memorial Sloan Kettering Cancer Center phase I trial is currently evaluating administration of autologous human Langerhans-type dendritic cells, electroporated with an mRNA vaccine encoding for TRP-2, to patients with IIB to IV stage melanoma, after appropriate surgical treatment (NCT01456104) [50].